Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RiMO-301 with Radiation in Advanced Tumors
NCT03444714Phase 1Completed
- Sponsor
- Coordination Pharmaceuticals, Inc.
- Start
- Apr 2018
- Primary completion
- Jun 2025
- Modality
- Inorganic Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RiMO-301 in solid tumor (advanced stage), sponsored by Coordination Pharmaceuticals, Inc. Primary endpoint: Maximum Tolerated Dose at 45 days. Started Apr 2018; status: completed.
02
Drugs
RiMO-301
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03444714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03444714.